Spark Therapeutics

Spark/Novartis eye gene therapy nears EU market – but at what price?

https://pharmaphorum.com/news/spark-novartis-eye-gene-therapy-luxturna/

Spark shares tank after haemophilia gene therapy safety signal

https://pharmaphorum.com/news/spark-shares-tank-after-haemophilia-gene-therapy-safety-signal/

Pfizer moves haemophilia gene therapy into phase 3

https://pharmaphorum.com/r-d/pfizer-haemophilia-b-gene-therapy/

Your Latest Ophthalmology News for SMi’s Ophthalmic Drugs 2018

https://pharmaphorum.com/partner-content/your-latest-ophthalmology-news-for-smis-ophthalmic-drugs-2018/

Priority review voucher prices fall again after Spark’s $110m sale

https://pharmaphorum.com/news/spark-sells-priority-review-voucher-to-jazz/

How Will Spark’s Approval Impact the Gene Therapy Field?

https://pharmaphorum.com/partner-content/will-sparks-approval-impact-gene-therapy-field/

Novartis snaps up ex-US partnership with Spark on gene therapy

https://pharmaphorum.com/news/novartis-snaps-ex-us-partnership-spark-gene-therapy/

Spark divides opinion with $850,000 gene therapy

https://pharmaphorum.com/news/spark-gene-therapy-cost/

FDA makes history, approving Spark’s eye gene therapy

https://pharmaphorum.com/news/luxturna-spark-therapeutics/

1 2

Close in 10 seconds

Pharmaphorum.com

Search